Alzamend Neuro, Inc.

US$1.41As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ALZNHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (81.47%)
Div yield —
ROE (163.23%)
Biotechnology
Beta (5Y) 0.43
PE TTM —
TSR TTM (44.27%)
Mkt cap US$6.804M
ROIC (101.96%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.69
20.16%
(14.02%)
Hold 7|10|4|2|6
2Q26
3Q26
4Q26
1Q27
Earnings per share$
0.01
0.01
0.01
0.01
(6.30%)
(7.47%)
(4.45%)
(1.34%)
Revenue$M
0.582
0.596
0.632
0.613
9.55%
15.55%
16.61%
7.11%
Peers (US$6.804M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
2.993
—
—
EBIT/Intx
0.572
0.113
0.128
Own earn%
(52.50)
(30.71)
(46.33)
Sh yield%
50.08
60.30
63.06
Owners
Insiders/Inst%
0.85
88.14
Short interest%
3.38
SBC / revenue%
1.21
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
18–28
$1 testx
—
Incr. ROIC%
5